We are live on
!
Find out more
Two Sigma Investments Portfolio holdings
AUM
$124B
1-Year Est. Return
33.93%
This Fund
S&P 500
This Quarter
Est. Return
+9.67%
1 Year Est. Return
+33.93%
3 Year Est. Return
+96.56%
5 Year Est. Return
+105.93%
10 Year Est. Return
+538.88%
AUM
$42.6B
AUM Growth
-$927M
(-2.1%)
Cap. Flow
-$4.42B
Cap. Flow
% of AUM
-10.38%
Top 10 Holdings %
Top 10 Hldgs %
9.02%
Holding
3,518
New
408
Increased
1,022
Reduced
1,392
Closed
532
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$244M |
| 2 |
Pfizer
PFE
|
+$234M |
| 3 |
Nike
NKE
|
+$201M |
| 4 |
Tesla
TSLA
|
+$200M |
| 5 |
S&P Global
SPGI
|
+$196M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$305M |
| 2 |
Advanced Micro Devices
AMD
|
+$241M |
| 3 |
Invesco QQQ Trust
QQQ
|
+$231M |
| 4 |
Merck
MRK
|
+$199M |
| 5 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$190M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.1% |
| 2 | Healthcare | 11.63% |
| 3 | Consumer Discretionary | 11.09% |
| 4 | Financials | 10.76% |
| 5 | Industrials | 9.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1801
Werewolf Therapeutics
HOWL
$19.3M
| $1.2M | ﹤0.01% |
185,059
+38,323
| +26% | +$223K |
|
1802
Sumitomo Mitsui Financial
SMFG
$164B
| $1.2M | ﹤0.01% |
101,800
-2,600
| -2% | -$27.9K |
|
1803
Hudbay
HBM
$12.3B
| $1.19M | ﹤0.01% |
170,426
-756,245
| -82% | -$4.4M |
|
1804
Similarweb
SMWB
$658M
| $1.19M | ﹤0.01% |
132,497
+81,759
| +161% | +$604K |
|
1805
DocGo
DCGO
$62.6M
| $1.19M | ﹤0.01% |
294,816
+248,616
| +538% | +$938K |
|
1806
Allient
ALNT
$1.92B
| $1.19M | ﹤0.01% |
33,378
-9,887
| -23% | -$295K |
|
1807
Prestige Consumer Healthcare
PBH
$2.6B
| $1.19M | ﹤0.01% |
16,349
+5,898
| +56% | +$394K |
|
|
PLYA
1808
DELISTED
Playa Hotels & Resorts
PLYA
| $1.18M | ﹤0.01% |
122,103
+49,974
| +69% | +$441K |
|
1809
Caribou Biosciences
CRBU
$164M
| $1.18M | ﹤0.01% |
229,747
-274,852
| -54% | -$1.69M |
|
1810
Bit Digital
BTBT
$482M
| $1.18M | ﹤0.01% |
+409,443
| New | +$1.13M |
|
|
KZR
1811
DELISTED
Kezar Life Sciences
KZR
| $1.17M | ﹤0.01% |
130,225
+8,600
| +7% | +$78.3K |
|
1812
Energy Recovery
ERII
$443M
| $1.17M | ﹤0.01% |
74,093
-46,983
| -39% | -$748K |
|
1813
AvePoint
AVPT
$2.71B
| $1.17M | ﹤0.01% |
147,637
+83,945
| +132% | +$660K |
|
|
GLDD
1814
DELISTED
Great Lakes Dredge & Dock
GLDD
| $1.17M | ﹤0.01% |
133,450
-83,958
| -39% | -$691K |
|
|
LONA
1815
LeonaBio Inc
LONA
$72.1M
| $1.17M | ﹤0.01% |
42,561
+12,154
| +40% | +$386K |
|
1816
Lam Research
LRCX
$390B
| $1.17M | ﹤0.01% |
12,000
-234,910
| -95% | -$20.7M |
|
|
CLDT
1817
Chatham Lodging
CLDT
$586M
| $1.17M | ﹤0.01% |
115,317
-28,194
| -20% | -$294K |
|
1818
Surgery Partners
SGRY
$2.03B
| $1.17M | ﹤0.01% |
39,068
-32,332
| -45% | -$1.01M |
|
|
DHIL
1819
DELISTED
Diamond Hill
DHIL
| $1.17M | ﹤0.01% |
7,559
-1,699
| -18% | -$265K |
|
1820
Solid Biosciences
SLDB
$900M
| $1.16M | ﹤0.01% |
87,388
+50,190
| +135% | +$470K |
|
|
MREO
1821
Mereo BioPharma
MREO
$47.3M
| $1.16M | ﹤0.01% |
351,729
+40,669
| +13% | +$138K |
|
1822
Riot Platforms
RIOT
$7.76B
| $1.16M | ﹤0.01% |
+94,616
| New | +$1.23M |
|
1823
Aptiv
APTV
$10.3B
| $1.16M | ﹤0.01% |
+14,532
| New | +$1.17M |
|
1824
Viatris
VTRS
$18.9B
| $1.16M | ﹤0.01% |
96,797
-1,034
| -1% | -$12.5K |
|
1825
CoreCivic
CXW
$3.19B
| $1.15M | ﹤0.01% |
73,840
-29,483
| -29% | -$430K |
|
Similar funds
VAM
Two Sigma Investments's Q1 2024 Portfolio in Review
As of Q1 2024, Two Sigma Investments held 3,518 positions worth $42.6B, down 2.1% from $43.5B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Two Sigma Investments withdrew a net $4.42B in Q1 2024, closing 532 positions and reducing 1,392 holdings. Its most notable exit was Rivian, an estimated $158M position sold in full.
By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 18% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Two Sigma Investments opened a new position in Pfizer worth $234M.
- Two Sigma Investments's largest Q1 2024 buy was Pfizer: 8,419,014 shares worth $234M.
- Two Sigma Investments added most to Gilead Sciences in Q1 2024, an estimated $244M increase.
- Two Sigma Investments's biggest Q1 2024 reduction was NVIDIA, cutting an estimated $305M.
- Two Sigma Investments fully exited Rivian in Q1 2024, selling an estimated $158M.
- Two Sigma Investments's ten largest holdings make up 9% of its $42.6B portfolio in Q1 2024.
- Two Sigma Investments opened 408 new positions and closed 532 in Q1 2024.
- Two Sigma Investments's portfolio value fell 2.1% quarter-over-quarter to $42.6B.
Based on Two Sigma Investments's 13F filing for Q1 2024, filed 15 May 2024.